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Dialysis patients are at increased risk for muscle wasting, and time efficient 48 
screening tests are required for to allow for early detection. Creatinine kinetics 49 
have been advocated to estimate lean body mass (LBM) in peritoneal dialysis 50 
(PD) patients, and can be readily calculated in clinical practice from peritoneal 51 
dialysate effluent and urine collections. Bioimpedance is increasingly available, 52 
and we compared methods in 434 PD patients (55% men, 33.3% diabetics), mean 53 
age 55.2±16.2 years. LBM was lower by creatinine kinetics (47.8±16.6 kg men, 54 
37.8±11.2 kg women) vs bioimpedance (53.2±11.5 kg men, 39.2±7.2 kg women), 55 
p<0.01. The prevalence of muscle wasting was much greater using creatinine 56 
kinetics (72.4% men, 52.4% women) vs bioimpedance (55.2% men, 37.3%), p<0.05. 57 
Estimates of LBM were much lower using creatinine kinetics compared to 58 
bioimpedance. Studies reporting the prevalence of muscle loss in PD patients will 59 
differ depending upon the method used to estimate muscle mass. 60 
 61 
Introduction 62 
Dialysis patients are at increased risk of muscle wasting, and muscle 63 
wasting is associated with increased risk for mortality. Peritoneal dialysis (PD) 64 
patients have additional protein losses in the spent dialysate. For routine clinical 65 
practice simple screening tests are required to detect muscle wasting 66 
(sarcopenia) at an early stage to allow for intervention. Several methods have 67 
been advocated for assessing lean body mass in dialysis patients and creatinine 68 
kinetics is one method supported by the Kidney Disease Outcome Quality 69 
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Initiative (KDOQI) clinical guidelines committee [1]. Creatinine kinetics have 70 
been used to estimate lean body mass in PD patients [2]. Bioimpedance devices 71 
are being increasingly used in clinical practice, and can be used to assess body 72 
composition [3], and studies have reported that bioimpedance provides 73 
equivalent results to dual-energy x-ray absorptiometry (DXA) in PD patients [4]. 74 
As the prevalence of muscle wasting varies considerably between studies in PD 75 
patients, we wished to compare the estimations of lean body mass using 76 
creatinine kinetics and bioimpedance to determine whether the method used 77 
changed the reported prevalence of muscle wasting. 78 
 79 
Materials and Methods 80 
Creatinine kinetics were calculated from corresponding 24-hour spent 81 
peritoneal dialysate effluents, 24-hour urine collections and serum samples, 82 
using standard equations [5], when patients attended for routine testing of 83 
peritoneal membrane function. Enzymatic methods were used to measured 84 
creatinine to exclude interference from glucose [6]. Multifrequency segmental 85 
bioimpedance was performed in a standardised manner after patients had voided 86 
and peritoneal dialysate drained out (InBody700, Seoul, Korea) [7]. The 87 
bioimpedance machine was regularly serviced and calibrated. Muscle wasting was 88 
defined by age and gender matched reference data obtained from the National 89 
Health and Nutritional Survey (NHANES) [8]. 90 
This retrospective audit complied with the UK National Health Service 91 
(NHS) guidelines for clinical audit and service development.  92 
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 93 
Statistical analysis 94 
Data is presented as mean ± standard deviation, median (interquartile 95 
range), or as percentage. Standard statistical tests were used to analyse data. 96 
using Prism 7.0 (Graph Pad, San Diego, USA) and SPSS 24 (SPSS, University of 97 
Chicago, Chicago, USA) and Analyse It 4.0 (Analyse-It, Leeds, UK). Statistical 98 
significance was taken as p<0.05.  99 
 100 
Results 101 
We compared lean body mass estimated by creatinine kinetics and 102 
bioimpedance in 434 PD patients (table 1). Lean body mass estimated by 103 
creatinine kinetics was lower for both men (47.8±16.6 kg) and women (37.8±11.2 104 
kg) vs bioimpedance (53.2±11.5 kg men, 39.2±7.2 kg women), p<0.01. The mean 105 
bias on Bland Altman analysis showed creatinine kinetics under-estimating lean 106 
body mass compared to bioimpedance by 3.8 kg (Figure 1), with mean bias less 107 
for women 1.6 kg (95% limits of agreement -18.5 to 21.8 kg), and 5.5 kg (-22.5 to 108 
33.5 kg). Using NHANES reference data, the prevalence of muscle wasting was 109 
72.4% for men and 52.4% for women by creatinine kinetics vs 55.2% for men 110 
and 37.3% for women using bioimpedance, p<0.05. Dividing patients according to 111 
ethnicity lean body mass was not statistically different (European: females 19.7 112 
(14.0-27.9), males 21.3 (14.7-33.4); Asian: females 19.1 (17.0-29.8), males 21.4 113 
(14.4-31.2); African Afro-Caribbean: females 19.8 (14.0-33.4), males 17.9 (12.9-114 




 Studies in dialysis patients have repeatedly reported that loss of muscle 118 
mass is strongly associated with an increased risk in mortality. Once established 119 
protein energy wasting is difficult to reverse, and as such simple screening tests 120 
are required for every day clinical practice. The routine samples obtained when 121 
PD patients attend for assessment of peritoneal membrane function allow 122 
estimation of lean body mass by calculating the creatinine index [5], and this 123 
method has been supported by the KDOQI committee [1]. A validation study of 124 
creatinine index reported similar estimates of lean body mass to those obtained 125 
with DXA in PD patients, although the number of patients studied was very small 126 
[2]. Bioimpedance devices are now more readily available in clinical practice, with 127 
estimates of body composition in both haemodialysis and PD patients reported 128 
to correlate strongly with DXA measurements [4,9]. 129 
Studies reporting on the prevalence of loss of muscle mass (sarcopenia) in 130 
dialysis patients have varied in results, and as such we wished to determine 131 
whether some of this variance could be due to the method used to estimate 132 
muscle mass. We found that creatinine kinetics under-estimated lean body mass 133 
compared to that measured with bioimpedance, and the mean bias was greater 134 
for men compared to women, as male dialysis patients typically have greater 135 
muscle mass and are more physically active [10]. We had too few anuric patients 136 
to determine whether potential differences in non-renal creatinine excretion 137 
and metabolism resulted in in greater bias, compared to those with residual 138 
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renal function. We did not find differences between ethnic groups, but this may 139 
have been due to analysis of small numbers and differences in patient 140 
demographics. Similarly we did not observe a difference with peritoneal 141 
transport status. 142 
When we then compared estimates of muscle mass with recognized age and 143 
gender matched reference data [7], we found that the prevalence of muscle loss 144 
(sarcopenia) was significantly greater when using creatinine kinetics. When 145 
calculating creatinine kinetics, although urinary and peritoneal creatinine can be 146 
measured by routine laboratory methods, the higher glucose concentration in 147 
the spent peritoneal dialysate effluent may interfere with standard Jaffe 148 
creatinine assays. To overcome this potential error, we used enzymatic methods. 149 
In the steady state, estimation of lean body mass and creatinine kinetics are 150 
closely correlated in healthy subjects, however in dialysis patients greater 151 
amounts of creatinine are secreted into the intestine, some of which is then 152 
reabsorbed, and then a variable proportion is converted back to creatine [5]. As 153 
such creatinine kinetics, potentially under-estimates lean body mass in patients 154 
with chronic kidney disease, and we found that the creatinine kinetics under-155 
estimated lean body mass compared to bioimpedance, with the mean bias being 156 
greater for male compared to female PD patients, leading to reporting a much 157 
higher prevalence of muscle wasting using creatinine kinetics compared to 158 
bioimpedance. Our study using bioimpedance supports previous studies which 159 
compared lean body mass estimated by creatinine kinetics with that using 160 
isotopic potassium [5]. We noted that there were wide limits of agreement 161 
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between methods for individual patients, which may relate to variation in dietary 162 
intakes and body composition.  163 
 Our study would suggest that creatinine kinetics is a less reliable method 164 
of assessing lean body mass in PD patients and leads to an over estimation of the 165 
prevalence of muscle wasting. 166 
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Figure 1: Bland Altman plot comparing lean body mass measured by 239 


















Table 1. Demographics of peritoneal dialysis patients used for estimation of lean 257 
body mass by Creatinine kinetics and Bioimpedance. Peritoneal dialysis modality, 258 
peritoneal membrane transport status, and urea dialysis clearance (weekly 259 
Kt/Vurea), laboratory tests and multifrequency bioimpedance body composition. 260 
Results shown as median (25th, 75th percentile) or number (percentage).   261 
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